Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

3.6K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.6K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

636
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
636
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

4.5K
Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
4.5K
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

913
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
913
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

1.2K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Letter to the editors.

Inflammatory bowel diseases·2026
Same author

Review Article: Implementation Challenges in Helicobacter pylori Management: Bridging Evidence and Real-World Practice.

Alimentary pharmacology & therapeutics·2026
Same author

Elucidating the Pathogenic Role of Helicobacter pylori Infection in Hematologic Disorders: Mechanistic Insights and Future Perspectives.

Helicobacter·2026
Same author

First Report of National Consensus Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Iran.

Helicobacter·2026
Same author

Characterization of three gut microbes and their toxins in cancerous and healthy tissues of Iranian patients with colorectal cancer.

Gastroenterology and hepatology from bed to bench·2026
Same author

A novel multi-epitope vaccine induces protective and therapeutic immunity against Helicobacter pylori.

NPJ vaccines·2026

Related Experiment Video

Updated: Jan 18, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.1K

Novel Enterococcus faecium P2 as a probiotic for mitigating Clostridioides difficile infection.

Yihong Cui1, Qianying Jia2, Han Yan1

  • 1Department of Pathogen Biology, College of Basic Medical Science, Chongqing Medical University, 400016, Chongqing, China.

Microbial Pathogenesis
|September 11, 2025
PubMed
Summary

Enterococcus faecium P2, a novel probiotic, effectively prevents Clostridioides difficile infection (CDI) in mice. This probiotic strengthens the gut barrier, reduces inflammation, and restores microbial balance, offering a promising therapeutic strategy for CDI.

Keywords:
Clostridioides difficileColitisEnterococcus faeciumProbiotics

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.6K
Production, Crystallization and Structure Determination of C. difficile PPEP-1 via Microseeding and Zinc-SAD
13:34

Production, Crystallization and Structure Determination of C. difficile PPEP-1 via Microseeding and Zinc-SAD

Published on: December 30, 2016

11.9K

Related Experiment Videos

Last Updated: Jan 18, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.1K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.6K
Production, Crystallization and Structure Determination of C. difficile PPEP-1 via Microseeding and Zinc-SAD
13:34

Production, Crystallization and Structure Determination of C. difficile PPEP-1 via Microseeding and Zinc-SAD

Published on: December 30, 2016

11.9K

Area of Science:

  • Microbiology
  • Gastroenterology
  • Immunology

Background:

  • Clostridioides difficile (C. difficile) causes severe intestinal diseases.
  • Probiotics show potential in managing gastrointestinal disorders.

Purpose of the Study:

  • To evaluate the probiotic efficacy of Enterococcus faecium (E. faecium) P2 against C. difficile infection (CDI).

Main Methods:

  • Isolated E. faecium P2 from healthy child's feces.
  • Performed in vitro safety and anti-C. difficile assays.
  • Assessed E. faecium P2 efficacy in a mouse model of CDI.
  • Analyzed intestinal barrier proteins, inflammatory markers, and fecal microbiota.

Main Results:

  • E. faecium P2 demonstrated safety, gastrointestinal stress tolerance, and inhibition of C. difficile growth and biofilm formation in vitro.
  • In vivo, prophylactic E. faecium P2 reduced CDI clinical scores and mortality.
  • E. faecium P2 enhanced intestinal barrier function by upregulating MUC-2, ZO-1, and Claudin-1.
  • The probiotic modulated inflammation by decreasing pro-inflammatory factors and increasing IL-10.
  • Fecal microbiota analysis indicated E. faecium P2 restored microbial balance.

Conclusions:

  • E. faecium P2 exhibits significant probiotic potential for preventing C. difficile infection.
  • This probiotic strengthens the intestinal barrier and modulates the immune response.
  • E. faecium P2 may serve as a valuable therapeutic agent for CDI management.